It is noteworthy that ABT-199 (Venetoclax), another BCL2 inhibitor targeting the BH3 domain and disrupting the BCL2/BAX interaction, has demonstrated synergy with other drugs in Acute Myeloid Leukaemia (AML) [43]. This evidence concerns the gene BAX and acute myeloid leukemia.